Trevena, Inc.

As of July 8, 2024, Trevena, Inc. is considered overvalued with negative valuation ratios and has significantly underperformed the market, with a year-to-date return of -83.33% compared to the S&P 500's 12.22%.

As of August 8, 2024, Trevena, Inc. is overvalued with negative financial ratios and a significant decline in stock performance, indicating a deteriorating valuation outlook compared to its peers.

As of June 17, 2025, Trevena, Inc. exhibits a mildly bearish trend, with mixed technical indicators showing a weak bearish sentiment overall.

As of March 2022, the management team of Trevena, Inc. includes Leon Moulder (Independent Chairman), Carrie Bourdow (CEO), and several independent directors: Maxine Gowen, Scott Braunstein, Michael Dougherty, Julie McHugh, and Jake Nunn. They oversee the company's strategic direction and operations.

Trevena, Inc. is a biopharmaceutical company focused on developing therapies for pain management and migraine treatment. As of September 2024, it reported net sales of $0 million and a net loss of $5 million, with a market cap of $0.95 million.

As of Jun 18, Trevena, Inc. has a market capitalization of 0.95 million, with net sales of 0.55 million and a net profit of -34.02 million over the latest four quarters. Shareholder's funds are at -7.66 million, and total assets are 40.60 million as of Dec 23.